ACT Brief: SCOPE Highlights Operational Discipline, AI Adoption Accelerates Execution, and FDA Rethinks Evidence Standards
ACT Brief: Predictive Analytics Advance, Collaborative Data Standards Scale, and Moderna’s Flu Vaccine Review Moves Forward
ACT Brief: AI Enables Real-Time Trial Oversight, Provider Engagement Strengthens Recruitment, and HHS Leadership Restructures Operations
ACT Brief: AI Moves Into Implementation, Digital Measurement Adoption Accelerates, and Global Trial Competition Intensifies
ACT Brief: eSource Moves Toward AI-Enabled Validation, Outsourcing Models Shift Toward Flexibility, and Robust Trial Design Becomes Mission Critical
ACT Brief: Regional Risk Variability Emerges, Patient Experience Drives Retention, and Digital Endpoints Scale in Oncology
ACT Brief: Real-World Data Connectivity Expands, AI Supports Smarter Data Capture, and Diversity Strategies Refocus at SCOPE
ACT Brief: AI Scales Trial Design, ESG Becomes a Readiness Test, and Sites Push Back on Payment Practices
ACT Brief: Purpose Meets Operational Focus, Acceleration Shifts Upstream, and AI Delivers Near-Term Impact
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
ACT Brief: RWE Refines Trial Design, Oncology CRO Scale Expands, and Feasibility Pressures Persist
ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline
ACT Brief: Decentralized Innovation Faces Reality, RWE Finds Its Lane, and Clinical Ops Reset for 2026
ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework
ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
ACT Brief: Life Sciences Hold the Line on DEI, Startup Timelines Stretch Further, and Regulators Align on AI Governance
ACT Brief: Signal Durability Redefines RBQM, AI Targets Startup Friction, and CDMOs Advance Patient-Centric Formulation
ACT Brief: Closing Gender Gaps in Parkinson’s Research, Startup Communication Breakdowns, and a New White House Healthcare Plan
ACT Brief: AI Extends Trial Registries, Contract Bottlenecks Delay Activation, and Data Integration Pushes Integrated Care
ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials
ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication
ACT Brief: EU Comparator Drug Sourcing Pressures, AI Expands Its Role in Oncology Trials, and Rethinking AI Value in Clinical Development
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval
ACT Brief: Persistent Barriers to Cancer Trial Participation, Clarifying IRT Data Ownership, and Clinical Trial Opportunities in Sub-Saharan Africa
ACT Brief: Support Services and Cancer Trial Access, 2025’s Most-Watched ACT Video Interviews, and FDA Approval of Narsoplimab
ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI
ACT Brief: AI-Enabled Workflow Automation, Subcutaneous Lunsumio VELO Approval, and Pan-KRAS Early-Stage Development
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer
ACT Brief: Training Community Oncology Sites, Digital Tools for Patient-Centric Trials, and New Phase III Momentum in Obesity R&D
ACT Brief: AI-Enabled COA Migration, Expanding Trial Footprints into Routine Care, and New FDA Approval in Myasthenia Gravis
ACT Brief: AI’s Impact on Trial Timelines, New Strategies in Obesity R&D, and Why Patient Support Needs a Clinical Backbone
ACT Brief: New CAR-T Trial Requirements, Pfizer Advances Oral GLP-1 Strategy, and Kisqali Shows Durable Long-Term Control
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
ACT Brief: AI-Driven Repurposing Advances, GCP Adoption Challenges, and New CAR-T Milestone
ACT Brief: CNS Trial Expansion, Vaccine Policy Debate, and New Leadership at FDA
ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA
ACT Brief: FDA’s Agentic AI Rollout, Exercise Interventions for Long COVID, and Patient-Centered Evidence Beyond the Trial
ACT Brief: Ultra-Compressed CNPV Review Timelines, New IgAN Therapy Approval, and Smarter Clinical Reference Data Strategies
ACT Brief: The Evolving CRA Role, New Immunotherapy Standard in Gastric Cancer, and Priority Review for Higher-Dose Wegovy
ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships
ACT Brief: AI-Driven Pharmacovigilance, Site-Led Digital Investments, and Smarter Multi-Touch Recruitment
next page